Table 1.
Demographics and clinical characterization of adults with TB.
| Category | Secondary Tuberculosis |
|---|---|
| Numbers | 72 |
| Age | 34[23,51.5] |
| Gender (F/M) | 28/44 |
| Vaccination status | |
| 3rd dose of inactivated vaccine | 23(31.94%) |
| 3rd dose of recombinant protein vaccine | 17(23.61%) |
| 2nd dose of inactivated vaccine | 16(22.22%) |
| Unvaccinated | 16(22.22%) |
| Disease stage* | |
| Active | 48(66.67%) |
| Improved | 12(16.67%) |
| Stable | 2(2.78%) |
| Tuberculosis infection site | |
| Unilateral lung | 23(31.94%) |
| Bilateral lung | 32(44.44%) |
| Bronchus | 19(26.39%) |
| Laryngeal | 2(2.78%) |
| Pleurisy | 6(8.33%) |
| Peritonitis | 1(1.38%) |
| Intestinal | 1(1.38%) |
| Comorbidity | |
| Drug-induced liver injury | 5(6.94%) |
| Type 2 diabetes mellitus | 11(15.28%) |
| Hypertension | 6(8.33%) |
| Hepatapostema | 2(2.78%) |
| Pulmonary emphysema | 3(4.17%) |
| Cerebral infarction | 2(2.78%) |
| Others a | 26(36.11%) |
| None | 22(30.56%) |
| Therapeutic regimen | |
| Isoniazid | 52(72.22%) |
| Rifampicin | 51(70.83%) |
| Rifapentine | 6(8.33%) |
| Ethambutol | 53(73.61%) |
| Pyrazinamide | 54(75.00%) |
| Levofloxacin | 23(31.94%) |
| Sodium Deoxyribonucleotide | 5(6.94%) |
| Bozhi Glycopeptide | 8(11.11%) |
| Kangfuxin Liquid | 17(23.61%) |
| Others b | 18(25.00%) |
| Positivity for purified protein derivative (PDD) test | 40(55.56%) |
| ESR(mm/h) | 14.5[6.75,43] |
| CRP(mg/L) | 5.05[1.65,21.88] |
⁎
Ten TB patients from outpatient have missed their complete medical history.
a
including: non-alcoholic fatty liver disease, anemia, carotid artery stenosis, hyponatremia, hypoproteinemia, fatty liver disease, coronary arteriosclerosis, lower limb vein thrombus, intestinal perforation, bronchiectasis, intestinal obstruction and chronic hepatitis.
b
including: amikacin, aztreonam, bedaquiline, ceftazidime, ceftriaxone, clofazimine, cycloserine, linezolid, moxifloxacin, pasiniazide, piperacillin, protionamide, tazobactam.